SCHEMBL13808697

SCHEMBL13808697

CCN(CC)c1ccc(C(=O)c2ccccc2C(=O)OCCN2C(=O)C=CC2=O)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ ALDH1A1 P00352 4/20 0.47
▸ GAA P10253 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ TSHR P16473 5/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ MAOB P27338 1/20 0.37
▸ MAPK1 P28482 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ CDC25B P30305 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ CYBB P04839 1/20 0.35
▸ NOX4 Q9NPH5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23571278 0.92 L3MBTL1 (0.54) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL669854 0.92 L3MBTL1 (0.54) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30025662 0.88 SMN1; SMN2 (0.50) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL23571279 0.88 SMN1; SMN2 (0.50) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13301476 0.87 L3MBTL1 (0.72) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL26556300 0.85 SMN1; SMN2 (0.47) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13301485 0.85 L3MBTL1 (0.69) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13301464 0.85 L3MBTL1 (0.69) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13301471 0.84 L3MBTL1 (0.67) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13301457 0.84 L3MBTL1 (0.67) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156485-A1 METHOD FOR COUPLING KERATIN-BINDING POLYPEPTIDES WITH EFFECTOR MOLECULES WHICH SUPPORT CARBOXYLIC GROUPS OR SULFONIC ACID GROUPS BASE SE (DE) 2009-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156485-A1 METHOD FOR COUPLING KERATIN-BINDING POLYPEPTIDES WITH EFFECTOR MOLECULES WHICH SUPPORT CARBOXYLIC GROUPS OR SULFONIC ACID GROUPS KRT18, KRTCAP2, CUTA L3MBTL1 4411/4885MEN1 3510/4885KMT2A 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback